Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P36871: Variant p.Thr115Ala

Phosphoglucomutase-1
Gene: PGM1
Feedback?
Variant information Variant position: help 115 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Threonine (T) to Alanine (A) at position 115 (T115A, p.Thr115Ala). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and polar (T) to small size and hydrophobic (A) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 0 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In CDG1T; reduces mildly phosphoglucomutase activity. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 115 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 562 The length of the canonical sequence.
Location on the sequence: help STPAVSCIIRKIKAIGGIIL T ASHNPGGPNGDFGIKFNISN The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         STPAVSCIIRKIKAI---GGIILTASHNPGGPNGDFGIKFNISN

Mouse                         STPAVSCIIRKIKAI---GGIILTASHNPGGPNGDFGIKFN

Rat                           STPAVSCIIRKIKAI---GGIILTASHNPGGPNGDFGIKFN

Bovine                        STPAVSCIIRKIKAI---GGIILTASHNPGGPNGDFGIKFN

Rabbit                        STPAVSCIIRKIKAI---GGIILTASHNPGGPNGDFGIKFN

Slime mold                    STPAISAIVRARSAL---GAIILTASHNPGGPNGDFGIKYN

Baker's yeast                 STPAASHIIRTYEEKCTGGGIILTASHNPGGPENDLGIKYN
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 562 Phosphoglucomutase-1
Active site 117 – 117 Phosphoserine intermediate
Binding site 117 – 117
Binding site 117 – 117 via phosphate groupe
Modified residue 115 – 115 Phosphothreonine
Modified residue 117 – 117 Phosphoserine
Modified residue 134 – 134 Phosphoserine
Alternative sequence 1 – 197 Missing. In isoform 3.



Literature citations
Muscle glycogenosis due to phosphoglucomutase 1 deficiency.
Stojkovic T.; Vissing J.; Petit F.; Piraud M.; Orngreen M.C.; Andersen G.; Claeys K.G.; Wary C.; Hogrel J.Y.; Laforet P.;
N. Engl. J. Med. 361:425-427(2009)
Cited for: INVOLVEMENT IN CDG1T; VARIANT CDG1T ALA-115; Multiple phenotypes in phosphoglucomutase 1 deficiency.
Tegtmeyer L.C.; Rust S.; van Scherpenzeel M.; Ng B.G.; Losfeld M.E.; Timal S.; Raymond K.; He P.; Ichikawa M.; Veltman J.; Huijben K.; Shin Y.S.; Sharma V.; Adamowicz M.; Lammens M.; Reunert J.; Witten A.; Schrapers E.; Matthijs G.; Jaeken J.; Rymen D.; Stojkovic T.; Laforet P.; Petit F.; Aumaitre O.; Czarnowska E.; Piraud M.; Podskarbi T.; Stanley C.A.; Matalon R.; Burda P.; Seyyedi S.; Debus V.; Socha P.; Sykut-Cegielska J.; van Spronsen F.; de Meirleir L.; Vajro P.; DeClue T.; Ficicioglu C.; Wada Y.; Wevers R.A.; Vanderschaeghe D.; Callewaert N.; Fingerhut R.; van Schaftingen E.; Freeze H.H.; Morava E.; Lefeber D.J.; Marquardt T.;
N. Engl. J. Med. 370:533-542(2014)
Cited for: VARIANTS CDG1T ALA-19; TYR-38; ARG-41; HIS-62; ALA-115; ARG-121; TYR-263; GLY-263; ARG-291; ARG-330; LYS-377; LYS-388 AND PRO-516; Compromised catalysis and potential folding defects in in vitro studies of missense mutants associated with hereditary phosphoglucomutase 1 deficiency.
Lee Y.; Stiers K.M.; Kain B.N.; Beamer L.J.;
J. Biol. Chem. 289:32010-32019(2014)
Cited for: CHARACTERIZATION OF VARIANTS CDG1T ALA-19; TYR-38; ARG-41; HIS-62; ALA-115; ARG-121; GLY-263; TYR-263; ARG-291; ARG-330; LYS-377; LYS-388 AND PRO-516; VARIANTS MET-68; CYS-221 AND HIS-420; FUNCTION; CATALYTIC ACTIVITY; BIOPHYSICOCHEMICAL PROPERTIES; ACTIVE SITE; PHOSPHORYLATION AT SER-117; ACTIVITY REGULATION;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.